FIRST EXPERIMENTS IN SPACE FOR COVID-19 DRUG RESEARCH
The COVID-19 pandemic has generated new and urgent challenges in drug discovery and development. Veklury®, a remdesivir-based medicament invented by
Tag: SBECD
Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (SBECD-enabled fosphenytoin)
Ligand Pharmaceuticals Incorporated announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration
U.S. FDA Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States — — Veklury Shortened Time to
Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing
Remdesivir, an investigational broad-spectrum antiviral agent, formulated with sulfobutyl beta-cyclodextrin, has shown in vitro activity against SARSCoV-2. Currently, remdesivir is
New cyclodextrin with orphan drug designation: SBECD
ReVision Therapeutics, Inc., a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular
Gilead debates WHO results on low effectivity of remdesivir in Covid-19 mortality rate
Pharmafile reports that Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections,
Combined therapy (remdesivir, dexamethasone and monoclonal antibodies) for the treatment of President Trump
Science News reported on October 5, 2020 the opinion of Rajesh Gandhi, an infectious diseases physician at Massachusetts General Hospital
Final Results of NIAID’s Trial Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19
— Final Day 29 Data Show Superior Efficacy of Veklury Compared with Placebo in Hospitalized Patients Receiving Standard of Care
Már Magyarországnak is van koronavírus elleni gyógyszere
Már gőzerővel gyártják Magyarországon a koronavírus elleni egyik leghatékonyabb gyógyszert – erősítette meg a Richter az Index értesüléseit. A RICHTER
Inclusion complex of chrysin with sulfobutyl ether-β-cyclodextrin
The work of Kulkarni and Belgamvar [1] demonstrates the impact of sulfobutyl ether-β-cyclodextrin (SBE-β-CD) complexation on the solubility, dissolution and